Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials
Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background. Abciximab has long-term efficacy in patients with STEMI undergoing PCI, bu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2022/3911414 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553668495278080 |
|---|---|
| author | Nan Bai Ying Niu Ying Ma Yao-Sheng Shang Peng-Yu Zhong Zhi-Lu Wang |
| author_facet | Nan Bai Ying Niu Ying Ma Yao-Sheng Shang Peng-Yu Zhong Zhi-Lu Wang |
| author_sort | Nan Bai |
| collection | DOAJ |
| description | Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background. Abciximab has long-term efficacy in patients with STEMI undergoing PCI, but the short-term efficacy is still controversial. Methods. We conducted a systematic review and meta-analysis compared with or without abciximab in patients with STEMI undergoing PCI. The relevant randomized controlled trials were included by searching PubMed, EMBASE, Cochrane Library, and Web of Science databases and other sources. The relative risk (RR) and 95% confidence intervals (CI) of outcomes were calculated by the fixed-effects model. Results. Ten randomized controlled trials with 5008 patients met inclusion criteria. There were no significant differences in risk of all-cause death at 30-day (RR 0.79, CI 0.55–1.12, P=0.18), major bleeding (1.37, 0.93–2.03, P=0.11), and transfusion (1.23, 0.94–1.61, P=0.13) between the two groups. However, there were significant differences in risk of all-cause death at 6 months (0.57, 0.36–0.90, P=0.02), recurrent myocardial infarction (0.55, 0.33–0.92, P=0.02), repeat revascularization (0.58, 0.43–0.78, P=0.0004), final TIMI flow <3 (0.77, 0.62–0.96, P=0.02), minor bleeding (1.29, 1.02–1.63, P=0.04), and thrombocytopenia (2.04, 1.40–2.97, P=0.0002). Conclusions. The application of abciximab can lead to a lower risk of reinfarction, revascularization, and all-cause death at 6 months, but a higher risk of minor bleeding, and thrombocytopenia. |
| format | Article |
| id | doaj-art-282252c90cd645bc8a68d12846da91b6 |
| institution | Kabale University |
| issn | 1540-8183 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-282252c90cd645bc8a68d12846da91b62025-02-03T05:53:27ZengWileyJournal of Interventional Cardiology1540-81832022-01-01202210.1155/2022/3911414Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical TrialsNan Bai0Ying Niu1Ying Ma2Yao-Sheng Shang3Peng-Yu Zhong4Zhi-Lu Wang5The First Clinical Medical College of Lanzhou UniversityThe First Clinical Medical College of Lanzhou UniversityThe First Clinical Medical College of Lanzhou UniversityThe First Clinical Medical College of Lanzhou UniversityThe First Clinical Medical College of Lanzhou UniversityDepartment of CardiologyObjectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background. Abciximab has long-term efficacy in patients with STEMI undergoing PCI, but the short-term efficacy is still controversial. Methods. We conducted a systematic review and meta-analysis compared with or without abciximab in patients with STEMI undergoing PCI. The relevant randomized controlled trials were included by searching PubMed, EMBASE, Cochrane Library, and Web of Science databases and other sources. The relative risk (RR) and 95% confidence intervals (CI) of outcomes were calculated by the fixed-effects model. Results. Ten randomized controlled trials with 5008 patients met inclusion criteria. There were no significant differences in risk of all-cause death at 30-day (RR 0.79, CI 0.55–1.12, P=0.18), major bleeding (1.37, 0.93–2.03, P=0.11), and transfusion (1.23, 0.94–1.61, P=0.13) between the two groups. However, there were significant differences in risk of all-cause death at 6 months (0.57, 0.36–0.90, P=0.02), recurrent myocardial infarction (0.55, 0.33–0.92, P=0.02), repeat revascularization (0.58, 0.43–0.78, P=0.0004), final TIMI flow <3 (0.77, 0.62–0.96, P=0.02), minor bleeding (1.29, 1.02–1.63, P=0.04), and thrombocytopenia (2.04, 1.40–2.97, P=0.0002). Conclusions. The application of abciximab can lead to a lower risk of reinfarction, revascularization, and all-cause death at 6 months, but a higher risk of minor bleeding, and thrombocytopenia.http://dx.doi.org/10.1155/2022/3911414 |
| spellingShingle | Nan Bai Ying Niu Ying Ma Yao-Sheng Shang Peng-Yu Zhong Zhi-Lu Wang Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials Journal of Interventional Cardiology |
| title | Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials |
| title_full | Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials |
| title_fullStr | Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials |
| title_full_unstemmed | Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials |
| title_short | Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials |
| title_sort | evaluate short term outcomes of abciximab in st segment elevation myocardial infarction patients undergoing percutaneous coronary intervention a meta analysis of randomized clinical trials |
| url | http://dx.doi.org/10.1155/2022/3911414 |
| work_keys_str_mv | AT nanbai evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials AT yingniu evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials AT yingma evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials AT yaoshengshang evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials AT pengyuzhong evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials AT zhiluwang evaluateshorttermoutcomesofabciximabinstsegmentelevationmyocardialinfarctionpatientsundergoingpercutaneouscoronaryinterventionametaanalysisofrandomizedclinicaltrials |